SAN DIEGO [April 5, 2022] – Trestle Biotherapeutics announced today that is has been selected as a “Cool Company” by Connect San Diego, an organization that helps promote San Diego’s top startups for funding.
SAN DIEGO [February 23, 2022] – Trestle Biotherapeutics, a private, San Diego-based company developing bioengineered therapies for patients living with kidney failure has today announced the formation of its advisory board. The Trestle Advisory Board is a balanced mix of academic and industry leaders who are world renowned scientific experts in the fields of 3D biofabrication, stem cell and developmental biology, tissue engineering, immunology, and nephrology.
SAN DIEGO–(BUSINESS WIRE)–Trestle Biotherapeutics, a private company based in San Diego, today announced that it has entered into a license agreement with Kumamoto University. Under the agreement, Trestle will gain access to foundational methods for the generation of specialized kidney cell types from human pluripotent stem cells.
SAN DIEGO–(BUSINESS WIRE)–Trestle Biotherapeutics, a private company based in San Diego, today announced that it has entered into a license agreement with Harvard University. Under the agreement, Trestle will commercialize a suite of stem cell- and 3D biofabrication-based regenerative medicine technologies developed at Harvard’s Wyss Institute for Biologically Inspired Engineering, Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS), and Brigham and Women’s Hospital.
Trestle Biotherapeutics highlighted by TechCrunch as one of top biotech companies at Y Combinator’s W21 Demo Day
Trestle Biotherapeutics is now backed by Y Combinator (YC), an elite start up accelerator that has launched more than 3000 companies, including Stripe, Airbnb, DoorDash, Coinbase, Instacart, Dropbox, Ginkgo Bioworks, and 64x Bio. Trestle accepted YC’s invitation to join the Winter 2021 cohort, and will be working directly with YC Partners Jared Friedman, Surbhi Sarna, and Tim Brady.
Founding scientists of Trestle co-author report describing use of automated bioprinting to enable human kidney organoid generation with improved throughput, reproducibility, scale, and nephron development. This work represents an important step forward in the areas of kidney tissue engineering and regenerative medicine.
Founding scientists of Trestle co-author report demonstrating proof-of-concept for automated production of human kidney organoids using a 3D bioprinter. This approach enables rapid generation of large numbers of kidney organoids for use in high content compound screening.